Diabetes research and clinical practice最新文献

Target gene variations of PPAR isoforms may contribute to MODY heterogeneity: A preliminary comparative study with type 2 diabetes PPAR 同工型的靶基因变异可能导致 MODY 的异质性：与 2 型糖尿病的初步比较研究。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-17 DOI: 10.1016/j.diabres.2024.111932

Hulya Yilmaz-Aydogan , Deniz Kanca-Demirci , Nurdan Gul , Cagatay Aydogan , Sukran Poyrazoglu , Yıldız Tutuncu , Fidan Malikova , Oguz Ozturk , Ilhan Satman

{"title":"Target gene variations of PPAR isoforms may contribute to MODY heterogeneity: A preliminary comparative study with type 2 diabetes","authors":"Hulya Yilmaz-Aydogan , Deniz Kanca-Demirci , Nurdan Gul , Cagatay Aydogan , Sukran Poyrazoglu , Yıldız Tutuncu , Fidan Malikova , Oguz Ozturk , Ilhan Satman","doi":"10.1016/j.diabres.2024.111932","DOIUrl":"10.1016/j.diabres.2024.111932","url":null,"abstract":"<div><h3>Aims</h3><div>The objective of this study was to evaluate the associations of several genetic variants of peroxisome proliferator-activated receptors (PPARs) on clinical and laboratory parameters in patients with maturity-onset diabetes of the young (MODY), and possible contribution to heterogeneity of the disease.</div></div><div><h3>Methods</h3><div>The study groups comprised patients with MODY (genetically confirmed (n = 28), clinically relevant but genetically unconfirmed; MODYX (n = 56)), type 2 diabetes mellitus (T2DM; n = 94) and healthy controls (n = 153). <em>PPARA</em>-L162V-(rs1800206), <em>PPARG-</em>C161T-(rs3856806), P12A-(rs1801282), and <em>PPARB/D</em> + 294 T/C-(rs2016520) polymorphisms were genotyped by real-time-PCR.</div></div><div><h3>Results</h3><div>The results demonstrated that the frequencies of <em>PPARA</em>-LL162 (p = 0.002), <em>PPARG-</em>CC161 (p = 0.002), and <em>PPARG-</em>ProPro (p = 0.012) genotypes were significantly higher in the MODY group compared to the controls. Furthermore, total-MODY and MODYX groups had a higher frequency of <em>PPARA</em>-LL162 genotype than T2DM (p = 0.005 and p = 0.006, respectively). The frequency of the <em>PPARB/D</em> + 294 T allele was significantly higher in individuals with T2DM than in genetically-determined MODY group (p = 0.019). The <em>PPARA</em>-LL162 genotype was associated with early-onset diabetes in total-MODY (p = 0.022) and T2DM (p < 0.05) groups.</div></div><div><h3>Conclusions</h3><div>The association of <em>PPARA</em>-L162V polymorphism with early-onset diabetes in both T2DM and MODY is a noteworthy finding. Considering these results, we suggested that genetic polymorphisms in <em>PPAR</em> isoforms may contribute to the clinical and metabolic heterogeneity of MODY.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111932"},"PeriodicalIF":6.1,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global, regional, and national burden of type 2 diabetes mellitus attributable to particulate matter pollution from 1990 to 2021: An analysis of the global burden of disease study 2021. 1990 年至 2021 年颗粒物污染对全球、地区和国家造成的 2 型糖尿病负担：2021 年全球疾病负担研究分析》。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-16 DOI: 10.1016/j.diabres.2024.111934

Diya Xie, Zhang Shen, Lihang Yang, Daosen Zhou, Cheng Li, Fengmin Liu

{"title":"Global, regional, and national burden of type 2 diabetes mellitus attributable to particulate matter pollution from 1990 to 2021: An analysis of the global burden of disease study 2021.","authors":"Diya Xie, Zhang Shen, Lihang Yang, Daosen Zhou, Cheng Li, Fengmin Liu","doi":"10.1016/j.diabres.2024.111934","DOIUrl":"10.1016/j.diabres.2024.111934","url":null,"abstract":"<p><strong>Aims: </strong>The study uses GBD 2021 data to measure the type 2 diabetes mellitus (T2DM) burden linked to particulate matter pollution (PM<sub>2.5</sub>) exposure, highlighting environmental factors as rising contributors to the disease.</p><p><strong>Methods: </strong>We used advanced methods like Joinpoint regression and decomposition analysis to track PM2.5 exposure's effects on T2DM, analyzing its burden by Socio-demographic indices (SDI) to find high-risk areas for targeted interventions.</p><p><strong>Results: </strong>In 2021, the global burden of T2DM attributable to PM<sub>2.5</sub> exposure reached 12,904,493 DALYs, a substantial increase from 1990. The age-standardized mortality rates (ASMR) and age-standardized death rates (ASDR) showed an upward trend, with males exhibiting a higher disease burden than females. The burden was highest in lower SDI quintiles, with faster growth rates in ASDR and ASMR compared to higher SDI regions. The population attributable fractions (PAFs) for ASDR and ASMR due to PM<sub>2.5</sub> were 17.07 % and 17.47 %, respectively, with higher PAFs in lower SDI regions.</p><p><strong>Conclusion: </strong>Our results show that air pollution significantly affects global T2DM rates, necessitating policies to lower PM2.5 and boost health system resilience. Ongoing monitoring and research are key to crafting strategies against pollution's health effects.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"111934"},"PeriodicalIF":6.1,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adequate sleep duration accentuates the effect of glucagon-like peptide-1 receptor variant on HbA1c: A gene-environment interaction study 充足的睡眠时间可加强胰高血糖素样肽-1 受体变异对 HbA1c 的影响：一项基因与环境相互作用的研究。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-12 DOI: 10.1016/j.diabres.2024.111927

Jiahe Wei , Hanzhang Wu , Ying Zheng , Ningjian Wang , Christian Benedict , Wei Chen , Xiao Tan

{"title":"Adequate sleep duration accentuates the effect of glucagon-like peptide-1 receptor variant on HbA1c: A gene-environment interaction study","authors":"Jiahe Wei , Hanzhang Wu , Ying Zheng , Ningjian Wang , Christian Benedict , Wei Chen , Xiao Tan","doi":"10.1016/j.diabres.2024.111927","DOIUrl":"10.1016/j.diabres.2024.111927","url":null,"abstract":"<div><h3>Background</h3><div>Both glucagon-like peptide-1 receptor (GLP1R) agonists and lifestyle modifications are widely adopted in managing glycemia. However, the joint effects of GLP1R agonists with lifestyle on glycemic traits have not been evaluated.</div></div><div><h3>Methods</h3><div>This gene-environment study tested the interaction between <em>GLP1R</em>-rs10305492 variant, consistent with the effect of GLP1R agonist therapies, and four lifestyle factors (diet, physical activity, sleep duration, and chronotype) for glucose and glycated hemoglobin (HbA1c) levels among 263,846 UK Biobank participants. Linear regression models were conducted to evaluate the effects of the rs10305492 and lifestyle factors on glucose and HbA1c levels.</div></div><div><h3>Results</h3><div><em>GLP1R</em>-rs10305492-AA/AG genotype combined a healthy diet, regular physical activity, adequate sleep duration, or morning chronotype were associated with lower glucose and HbA1c levels (all <em>P</em> for trend < 0.001). A synergistic effect was found between rs10305492 and sleep duration on HbA1c, suggesting a recommended adequate sleep duration (7–8 h/day) may amplify the HbA1c lowering effect of GLP1R agonists. Joint effects of the rs10305492 and adequate sleep were associated with a 26 % reduced risk of hyperglycemia (>7.8 mmol/L) risk and a 22 % lower of high HbA1c (>39 mmol/mol or 5.7 %).</div></div><div><h3>Conclusions</h3><div>Combining GLP1R agonists with adequate sleep may provide additional benefits for glycemic control in clinical practice.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111927"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postpartum dysglycaemia after early gestational diabetes: Follow-up of women in the TOBOGM randomised controlled trial 早期妊娠糖尿病后的产后血糖异常：TOBOGM随机对照试验中妇女的随访。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-12 DOI: 10.1016/j.diabres.2024.111929

N. Wah Cheung , Yoon J.J. Rhou , Jincy Immanuel , William M. Hague , Helena Teede , Christopher J. Nolan , Michael J. Peek , Jeff R. Flack , Mark McLean , Vincent W. Wong , Emily J. Hibbert , Alexandra Kautzky-Willer , Jürgen Harreiter , Helena Backman , Emily Gianatti , Arianne Sweeting , Vishwanathan Mohan , David Simmons

{"title":"Postpartum dysglycaemia after early gestational diabetes: Follow-up of women in the TOBOGM randomised controlled trial","authors":"N. Wah Cheung , Yoon J.J. Rhou , Jincy Immanuel , William M. Hague , Helena Teede , Christopher J. Nolan , Michael J. Peek , Jeff R. Flack , Mark McLean , Vincent W. Wong , Emily J. Hibbert , Alexandra Kautzky-Willer , Jürgen Harreiter , Helena Backman , Emily Gianatti , Arianne Sweeting , Vishwanathan Mohan , David Simmons","doi":"10.1016/j.diabres.2024.111929","DOIUrl":"10.1016/j.diabres.2024.111929","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate the incidence and predictors of postpartum dysglycaemia among high-risk women who develop early gestational diabetes (eGDM) prior to 20 weeks’ gestation.</div></div><div><h3>Methods</h3><div>This is a sub-study of the Treatment of Booking Gestational Diabetes (TOBOGM) Study, a randomised controlled trial of early or deferred treatment for women with risk factors for gestational diabetes diagnosed with eGDM, using current WHO criteria. Overt diabetes in pregnancy was excluded. A repeat oral glucose tolerance test (oGTT) was recommended at 6–12 weeks postpartum.</div></div><div><h3>Results</h3><div>Of 793 participants, 352 (44.4%) underwent a postpartum oGTT. Baseline characteristics of participants with and without an oGTT were similar. Ninety-two (26.1%) had postpartum dysglycaemia: 11 (3.1%) diabetes, 31 (8.8%) impaired fasting glucose (IFG), 39 (11.1%) impaired glucose tolerance (IGT), and 11 (3.1%) combined IFG/IGT. Participants with postpartum dysglycaemia were more likely to have had past GDM, lower body mass index, more gestational weight gain, and higher 1 and 2-hour glucose concentrations on the early pregnancy oGTT. On logistic regression, higher 1 and 2-hour glucose concentration, previous GDM and greater gestational weight gain were independently associated with postpartum dysglycaemia.</div></div><div><h3>Conclusion</h3><div>There is a high incidence of postpartum dysglycaemia among high-risk women with eGDM.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111929"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis 接受免疫检查点抑制剂治疗的非小细胞肺癌患者中糖尿病的预后意义：荟萃分析

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-12 DOI: 10.1016/j.diabres.2024.111930

Nam Nhat Nguyen , Thu Huynh Ha Nguyen , Kinh Dinh Hoang , Thai Kien Vo , Quan Hoang Minh Pham , Yang Ching Chen

{"title":"The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","authors":"Nam Nhat Nguyen , Thu Huynh Ha Nguyen , Kinh Dinh Hoang , Thai Kien Vo , Quan Hoang Minh Pham , Yang Ching Chen","doi":"10.1016/j.diabres.2024.111930","DOIUrl":"10.1016/j.diabres.2024.111930","url":null,"abstract":"<div><h3>Aims</h3><div>Studies on the prognosis of patients with diabetes and non-small-cell lung cancer (NSCLC) in the era of immune checkpoint inhibitors (ICIs) are limited, and existing findings remain inconsistent. This meta-analysis explored the association between diabetes and survival outcomes in this population.</div></div><div><h3>Methods</h3><div>A total of 10 non-randomized studies comparing overall survival between patients with NSCLC receiving ICIs with and without diabetes were included. A meta-analysis was performed to estimate the hazard of death or disease progression between the two groups. Another analysis was employed to explore the difference in median survival between the groups. Additionally, subgroup, meta-regression, and sensitivity analyses were conducted.</div></div><div><h3>Results</h3><div>Patients with diabetes exhibited a significantly higher risk of death than those without diabetes (HR = 1.28, 95 % CI = 1.14–1.44; <em>P</em> < 0.01). Moreover, individuals with diabetes had a median life expectancy that was 6.04 months shorter (95 % CI = −10.53 to − 1.54 months, <em>P</em> = 0.009) than that of individuals without diabetes. Moreover, for every 1 % increase in the proportion of patients with diabetes using metformin, a corresponding 2.2 % decrease in the HR of progression-free survival was observed (95 % CI = 1.2–3.1 %).</div></div><div><h3>Conclusion</h3><div>Diabetes compromises the effectiveness of ICI treatment in patients with NSCLC.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111930"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased prevalence of cardiovascular-kidney-metabolic syndrome during COVID-19: A propensity score-matched study. COVID-19 期间心血管-肾脏-代谢综合征患病率增加：倾向得分匹配研究

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-12 DOI: 10.1016/j.diabres.2024.111926

Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Ugo Trama, Maria Lembo, Roberto Piccinocchi, Paola Gallo, Giovanni Esposito, Carmine Morisco, Francesco Rozza, Pasquale Mone, Stanislovas S Jankauskas, Gaetano Piccinocchi, Gaetano Santulli, Bruno Trimarco

{"title":"Increased prevalence of cardiovascular-kidney-metabolic syndrome during COVID-19: A propensity score-matched study.","authors":"Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Ugo Trama, Maria Lembo, Roberto Piccinocchi, Paola Gallo, Giovanni Esposito, Carmine Morisco, Francesco Rozza, Pasquale Mone, Stanislovas S Jankauskas, Gaetano Piccinocchi, Gaetano Santulli, Bruno Trimarco","doi":"10.1016/j.diabres.2024.111926","DOIUrl":"10.1016/j.diabres.2024.111926","url":null,"abstract":"<p><p>A recent presidential advisory from the American Heart Association (AHA) has introduced the term cardiovascular-kidney-metabolic (CKM) syndrome to describe the complex interplay among health conditions linking heart, kidney, and metabolism. The aim of our study was to compare the prevalence of concurrent CKM syndrome components before and during the COVID-19 pandemic and identify associated risk factors. We conducted a study utilizing data from a real-world population obtained from a primary care database. The study cohort comprised a closed group followed over a 6-year period (2017-2022). A total of 81,051 individuals were included: 32,650 in the pre-pandemic period and 48,401 in the 2020-2022 triennium. After propensity-score matching for sex, age, and BMI, the study included 30,511 participants for each period. 3554 individuals were diagnosed with type 2 diabetes in the pre-pandemic period, compared to 7430 during the pandemic. Hypertension, dyslipidemia, and obesity displayed significant increases in prevalence during the pandemic, and prediabetes had a particularly sharp rise of 170%. Age-stratified analyses revealed a higher burden of CKM conditions with advancing age. Our findings indicate a substantial increase in the prevalence of CKM syndrome during the COVID-19 pandemic, with nearly half of the patients exhibiting one or more CKM syndrome components.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"111926"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perceptions and understanding of family pediatricians regarding the new Italian Type 1 Diabetes screening program 家庭儿科医生对意大利新的 1 型糖尿病筛查计划的看法和理解。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-12 DOI: 10.1016/j.diabres.2024.111931

Johara Mari , Sara Solidoro , Cinzia Braida , Gianluca Tamaro , Elena Faleschini , Gianluca Tornese

{"title":"Perceptions and understanding of family pediatricians regarding the new Italian Type 1 Diabetes screening program","authors":"Johara Mari , Sara Solidoro , Cinzia Braida , Gianluca Tamaro , Elena Faleschini , Gianluca Tornese","doi":"10.1016/j.diabres.2024.111931","DOIUrl":"10.1016/j.diabres.2024.111931","url":null,"abstract":"<div><h3>Aims</h3><div>Italy is the first country to implement a nationwide Type 1 Diabetes (T1D) screening program aimed at reducing cases of diabetic ketoacidosis and potentially delaying disease progression through early interventions. This study assesses the knowledge, perceptions, and willingness of family pediatricians (FPs) to participate in this program.</div></div><div><h3>Methods</h3><div>An anonymous online survey was conducted among 113 FPs in the Friuli Venezia Giulia region, an area not included in the initial pilot study. The survey evaluated their knowledge, readiness, and concerns regarding the screening program.</div></div><div><h3>Results</h3><div>Of the 62 respondents (55% response rate), 84% expressed a willingness to participate in the screening program, although most reported limited knowledge about it. The key concerns included family anxiety, identifying individuals at risk of diabetes, and uncertainty regarding follow-up procedures. While FPs acknowledged the potential benefits of reducing ketoacidosis, 75% emphasized the need for more training and support.</div></div><div><h3>Conclusions</h3><div>While FPs are largely willing to participate in the T1D screening program, significant gaps in knowledge and preparedness remain. Addressing these gaps through comprehensive education and clear follow-up protocols is crucial for the successful nationwide implementation of the program in 2025.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111931"},"PeriodicalIF":6.1,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years. 口服塞马鲁肽的实际效果：关注 75 岁以上的 2 型糖尿病患者。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-11 DOI: 10.1016/j.diabres.2024.111928

Walter Baronti, Cristina Lencioni, Margherita Occhipinti, Antonio Nicolucci, Graziano Di Cianni

{"title":"Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.","authors":"Walter Baronti, Cristina Lencioni, Margherita Occhipinti, Antonio Nicolucci, Graziano Di Cianni","doi":"10.1016/j.diabres.2024.111928","DOIUrl":"https://doi.org/10.1016/j.diabres.2024.111928","url":null,"abstract":"<p><strong>Aim: </strong>Data on the efficacy of oral semaglutide (OS) in elderly patients with type 2 diabetes are still lacking. This study evaluates the effectiveness of OS in a real world setting with a large ≥75 year old population.</p><p><strong>Methods: </strong>This study includes all type 2 diabetic patients who started OS between October 2021 and December 2023 in seven diabetes centers. Data were collected at baseline, 6 (T6) and 12 (T12) months. Effectiveness measures were assessed on the total sample and by patient age (<65, 65-75, >75 years).</p><p><strong>Results: </strong>Overall 1824 patients started OS, of those 18.7 % were over 75 years (>75 yr). OS resulted in a significant reduction in rate of patients using sulphonylureas, rapid and basal insulin therapy, HbA1c reduced by 0.87 % at T6 and at T12 (both p < 0.0001), body weight by 2.78 Kg (p < 0.0001) at T6 and 3.89 Kg (p < 0.0001) at T12. Similarly, >75 yr showed HbA1c reduction at T6 (p < 0.0001) and T12 (p = 0.0003), body weight significantly reduced (p for interaction 0.005) both at T6 (-1.57 Kg; p = 0.0003) and T12 (-2.74 Kg; p < 0.0001).</p><p><strong>Conclusion: </strong>In our study, OS results efficacy in non-elderly and elderly patients, making it an effective treatment option also for very elderly type 2 diabetic patients.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"111928"},"PeriodicalIF":6.1,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between liver steatosis, fibrosis, and the onset of type 2 diabetes in overweight individuals: A fibroscan-based study in Southern Italy 超重人群肝脏脂肪变性、纤维化与 2 型糖尿病发病之间的关系：一项基于纤维扫描的意大利南部研究。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-07 DOI: 10.1016/j.diabres.2024.111911

Davide Guido , Nicole Cerabino , Martina Di Chito , Vincenza Di Stasi , Sara De Nucci , Endrit Shahini , Vito Giannuzzi , Raffaele Cozzolongo , Sergio Coletta , Dolores Stabile , Anna Ancona , Giovanna Longo , Luigi Fontana , Gianluigi Giannelli , Giovanni De Pergola

{"title":"Association between liver steatosis, fibrosis, and the onset of type 2 diabetes in overweight individuals: A fibroscan-based study in Southern Italy","authors":"Davide Guido , Nicole Cerabino , Martina Di Chito , Vincenza Di Stasi , Sara De Nucci , Endrit Shahini , Vito Giannuzzi , Raffaele Cozzolongo , Sergio Coletta , Dolores Stabile , Anna Ancona , Giovanna Longo , Luigi Fontana , Gianluigi Giannelli , Giovanni De Pergola","doi":"10.1016/j.diabres.2024.111911","DOIUrl":"10.1016/j.diabres.2024.111911","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to explore the association between liver steatosis and fibrosis, as assessed by Fibroscan, and the onset of type 2 diabetes in overweight, medication-free men and women.</div></div><div><h3>Methods</h3><div>We analyzed data from 164 participants with overweight or obesity (41.4 % male), including 39 individuals (23.8 %) with type 2 diabetes. All participants underwent Fibroscan to evaluate liver steatosis (CAP > 275 dBm) and fibrosis (liver stiffness > 8.2 kPa). Diabetes was diagnosed using fasting glucose, 2-hour glucose tolerance test (OGTT), and HbA1c levels.</div></div><div><h3>Results</h3><div>Liver steatosis was significantly more prevalent in individuals with diabetes (89.7 % vs 52 %, P < 0.001). Liver fibrosis was observed in 35.9 % of subjects with diabetes (vs 13.6 %, P = 0.002). Mean CAP (P < 0.001) and kPA (P = 0.006) values were significantly higher in the group with diabetes. Significant associations between CAP (MD: 30.87, P = 0.009) and liver stiffness (MD: 2.454, P = 0.006) with diabetes were found, independent of other variables. Additionally, liver steatosis was independently associated with elevated HOMA-IR levels (P = 0.001).</div></div><div><h3>Conclusion</h3><div>Elevated liver steatosis and fibrosis are both linked to type 2 diabetes, independent of traditional risk factors. These findings support screening for diabetes in individuals with significant steatosis and fibrosis and vice versa.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111911"},"PeriodicalIF":6.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Curalin supplement as add-on therapy for type 2 diabetes Mellitus 将 Curalin 补充剂作为 2 型糖尿病的附加疗法。

IF 6.1 3区医学

Diabetes research and clinical practice Pub Date : 2024-11-06 DOI: 10.1016/j.diabres.2024.111912

Itamar Raz , Roni Weinberg Sibony , Saar Dor , Aliza Rozenberg , Ilan Yanuv , Ofer Yigdal , Ron Elul , Omri Segev

{"title":"Curalin supplement as add-on therapy for type 2 diabetes Mellitus","authors":"Itamar Raz , Roni Weinberg Sibony , Saar Dor , Aliza Rozenberg , Ilan Yanuv , Ofer Yigdal , Ron Elul , Omri Segev","doi":"10.1016/j.diabres.2024.111912","DOIUrl":"10.1016/j.diabres.2024.111912","url":null,"abstract":"<div><h3>Aims</h3><div>To examine the efficacy and safety of Curalin, as a supplement to anti-diabetic drugs (ADD).</div></div><div><h3>Methods</h3><div>135 patients were enrolled in the study. Among them, 109, ages 18–85 years, with HA1c 7.5–10 % under treatment with ADD were randomized 1:1 to receive Curalin supplement or placebo. The primary efficacy endpoint was the change in HbA1c after 3 months. The secondary endpoint was a decrease in HbA1c by more than 0.5 % and by more than 1 %. The exploratory endpoints included the Diabetes Treatment Satisfaction Questionnaire (DTSQ), clinical and laboratory results.</div></div><div><h3>Results</h3><div>After 3 months, the mean reduction in HbA1c was 1.30 % (SD = 0.79) in the Curalin group compared to 0.10 % (SD = 0.70) in the placebo group (P < 0.0001). A decrease in HbA1c of ≥ 0.5 % was observed in 90.0 % of Curalin patients versus 19.0 % of placebo patients (P < 0.0001). HbA1c reduction of ≥ 1 % occurred in 64.0 % of Curalin patients and 11.9 % of placebo patients (P < 0.0001). Curalin patients reported higher satisfaction (DTSQ) with no severe adverse events.</div></div><div><h3>Conclusions</h3><div>Curalin treatment significantly reduced HbA1c over a period of 3 months and was well-tolerated.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111912"},"PeriodicalIF":6.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0